...
首页> 外文期刊>Journal of neural transmission >Expression of CB(1) cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.
【24h】

Expression of CB(1) cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.

机译:CB(1)大麻素受体在精神分裂症,双相情感障碍和严重抑郁症的前扣带回皮层中表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The human endogenous cannabinoid system is an appealing target in the investigation of psychiatric disorders. In schizophrenia, endocannabinoids and their receptors are involved in the pathology of the disease. Previous studies reported an increased radioligand binding to cannabinoid receptors 1 (CB(1)) in schizophrenia, both in the dorsolateral prefrontal cortex and in the anterior cingulate cortex (ACC). We analyzed the expression of the CB(1) receptors in the ACC at the protein level using immunohistochemistry. In a quantitative postmortem study, 60 patients suffering from schizophrenia, bipolar disorder, major depression and controls were included. Numerical densities of neurons and glial cells immunopositive for CB(1) receptors were evaluated. No evidence of an increased or decreased density of CB(1) receptor immunopositive cells in schizophrenia or bipolar disorder was found. In major depression, CB(1) receptor immunopositive glial cells in the grey matter were decreased. Furthermore, our data show that different medications have an impact on the expression of CB(1) receptors in the ACC.
机译:人类内源性大麻素系统是精神疾病研究中吸引人的目标。在精神分裂症中,内源性大麻素及其受体参与了该疾病的病理过程。先前的研究报道,在背外侧前额叶皮层和前扣带回皮层(ACC)中,精神分裂症患者的大麻素受体1(CB(1))的放射性配体结合增加。我们使用免疫组织化学分析了ACC在蛋白质水平上的CB(1)受体的表达。在一项定量验尸研究中,纳入了60例患有精神分裂症,躁郁症,重度抑郁症和对照的患者。评估CB(1)受体免疫阳性的神经元和神经胶质细胞的数字密度。没有证据表明精神分裂症或双相情感障碍中的CB(1)受体免疫阳性细胞密度增加或降低。在严重抑郁症中,灰质中的CB(1)受体免疫阳性神经胶质细胞减少。此外,我们的数据表明,不同的药物对ACC中CB(1)受体的表达有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号